MIPS # PIMSH 9 Supportive Care Drugs in Last 14 Days

MEASURE DESCRIPTION

Percentage of patients receiving supportive care drugs (including colony stimulating factors, bone health, supplemental iron medications, and neurokinin 1 (NK1) receptor antagonist antiemetics) during the 14 days prior to and including the date of death.

This is an inverse measure; a lower score is better.

Relevance to Value Based Care

Clinically, there is little need for supportive care drug use in the last 14 days of life. Current studies show that chemotherapy and supportive care drugs continue to be the highest cost drivers, and it is critical to monitor appropriate use.

 Numerator

Patients who received supportive care drugs (including colony stimulating factors, bone health, supplemental iron medications, and neurokinin 1 (NK1) receptor antagonist antiemetics) during the 14 days prior to and including the date of death.

 Denominator

All cancer patients (solid or hematologic tumor) with a documented cancer-related date of death within the reporting period.

Exclusion/Exceptions

Failure of 5-HT3 receptor antagonists to treat nausea where NK1 receptor antagonists may be an appropriate course of patient care.

 Scoring

Up to 10 points

 RESOURCES